Hantavirus vs COVID-19: How the Presentation Diverges
Both start the same way — fever, exhaustion, aching — and one of them kills more than a third of the people who reach its second phase. This page sets hantavirus pulmonary syndrome beside COVID-19 on the network's data records and on presentation, because the numbers only mean something once the two denominators are understood: "38%" and "0.2–0.51%" are not measuring the same thing.
How to read this page. The tables are the network's two data records side by side — nothing is re-typed, so a figure here is exactly the figure on each virus's own page, with the same source, tier and date. A fatality rate is only comparable when its denominator is the same, and it usually is not; each cell carries its denominator note, and the prose below says which comparisons hold and which do not. An empty cell is a stated absence of measurement, not a low number.
The Figures, Side by Side
Hantavirus (hantavirus pulmonary syndrome, US)
A group of viruses spread chiefly by breathing in air contaminated with infected rodent droppings, urine, or saliva; in the Americas it can cause hantavirus pulmonary syndrome, a severe and sometimes fatal lung disease.
Established in the US A rare US disease — roughly a few dozen cases a year — concentrated in the rural western states.
COVID-19 (SARS-CoV-2)
A respiratory illness caused by the SARS-CoV-2 coronavirus and spread mainly through the air; most cases are mild, but it can cause severe pneumonia, especially in older adults and people with underlying conditions.
Common in the US Circulates year-round across the US and is one of the country's leading causes of respiratory hospitalization and death.
United States, side by side
| Metric | Hantavirus (hantavirus pulmonary syndrome, US) | COVID-19 (SARS-CoV-2) |
|---|---|---|
| Annual Exposure / Cases | Data not available | 10,400,000–16,700,000 CDC MMWR — Respiratory Virus Activity, United States, July 1, 2024–June 30, 2025 primary source as of 2026-02-19 |
| Severe Outcome Rate | Data not available | Data not available |
| Hospitalization Rate | Data not available | Data not available |
| Case Fatality Rate | 38% CDC — Reported Cases of Hantavirus Disease primary source as of 2026-09-15 Of people who develop respiratory symptoms (CDC's About Hantavirus page). CDC's surveillance page separately reports 35% across all 890 laboratory-confirmed hantavirus disease cases 1993–2023, including 31 non-pulmonary infections; the 38% is kept here because it describes clinical HPS, the syndrome this record is about. | 0.2–0.51% CDC MMWR — Respiratory Virus Activity, United States, July 1, 2024–June 30, 2025 primary source as of 2026-02-19 Of symptomatic illnesses (2024–25 modeled season); varies widely by variant, age, and vaccination. |
| Annual Deaths | Data not available | 34,000–53,000 CDC MMWR — Respiratory Virus Activity, United States, July 1, 2024–June 30, 2025 primary source as of 2026-02-19 |
| Reported cases per 100,000 residents | Data not available | Data not available |
Hantavirus (hantavirus pulmonary syndrome, US) — record note: CDC's own page (dated 2026-04-23) reports only a cumulative total (890 cases, 1993-2023; 859 HPS + 31 non-pulmonary), not a clean single-year annual figure, so annual_exposure_or_cases_estimate is UNAVAILABLE rather than substituting the cumulative number. CDC's weekly NNDSS tables give provisional annual HPS counts — 20 in 2024, 38 in 2025 — but year-end provisional counts are routinely revised upward by a third or more, so they are not used as an annual figure either. case_fatality_rate_pct (38%) is specifically for hantavirus pulmonary syndrome once respiratory symptoms develop. severe_outcome_rate_pct/hospitalization_rate_pct left UNAVAILABLE after a Phase B literature search: HPS by clinical case definition already involves respiratory failure, so a distinct 'hospitalization rate' may not be a meaningful CDC/literature statistic; the only figure found (67% required mechanical ventilation) came from a 12-patient pediatric case series, too narrow to represent the general population.
COVID-19 (SARS-CoV-2) — record note: Illness/hospitalization/death figures are Oct 1, 2024–Jul 5, 2025 modeled range estimates; COVID-19 is no longer nationally notifiable, so no clean confirmed-case count exists. cases_per_100k is left UNAVAILABLE. case_fatality_rate_pct is now shown as a BOUNDING RANGE (0.2-0.5%) rather than a point: the low bound is the smallest deaths / largest illnesses and the high bound the reverse, so it honestly spans the uncertainty in the two published ranges instead of inventing a single pairing. The 'How a figure changes over time' trend for COVID shows two honestly-separate NCHS death-certificate series (they must not be merged): deaths involving COVID-19 (underlying or contributing) — 377,883 (2020), 460,513 (2021), 244,986 (2022), 76,446 (2023) — and the narrower underlying-cause-only count — 345,323 (2020), 415,399 (2021), 186,702 (2022), 49,928 (2023). Both use a different method than the current-season modeled figure shown as the live value, so they are not directly comparable to it.
Sources behind every figure above
- CDC — Reported Cases of Hantavirus Disease primary source as of 2026-09-15
- WHO — Hantavirus fact sheet primary source as of 2026-05-06
- CDC MMWR — Respiratory Virus Activity, United States, July 1, 2024–June 30, 2025 primary source as of 2026-02-19
- WHO — COVID-19 dashboard: deaths reported to WHO (data through 30 August 2026) primary source as of 2026-08-30
What the Comparison Shows
The fatality figures are not the same kind of number. Hantavirus's 38% is CDC's rate among people who develop respiratory symptoms — that is, who reach the cardiopulmonary phase of hantavirus pulmonary syndrome (HPS). COVID-19's 0.2–0.51% is of all symptomatic illnesses in a modelled season, most of them mild. The first is a "given that you are already seriously ill" rate; the second is a "given that you got sick at all" rate. Put both in one sentence — "hantavirus is 100 times deadlier than COVID" — and the sentence is arithmetically true and epidemiologically meaningless. The denominator notes on the cells above are there to stop that sentence being written.
Scale is the opposite way round. COVID-19 causes 10.4–16.7 million US illnesses and 34,000–53,000 deaths a year; hantavirus disease has produced 890 US cases in the thirty-one years from 1993 to 2023 — CDC publishes no annual figure, so the record leaves the cell unavailable rather than substituting the cumulative number. Roughly a few dozen cases a year, concentrated in the rural West, against a virus that circulates everywhere year-round.
How the presentations diverge — the reason the comparison is searched for. The hantavirus spoke's symptoms page sets HPS beside influenza on the features that separate them, and the same features separate it from COVID-19:
- Onset window. HPS symptoms appear 1–8 weeks after exposure to rodent material. A patient who cleaned out a shed a month ago and now has a fever is in the window.
- The prodrome. Fever, severe fatigue and intense muscle aches in the thighs, hips and lower back — "often described as the most intense muscle pain the patient has experienced" — with nausea, vomiting, diarrhea and abdominal pain common. Runny nose and sore throat are rare, and respiratory symptoms are absent early. In the Omicron era, COVID-19 typically presents with sore throat, runny nose, fatigue and headache, as the coronavirus spoke's variants page records — the upper-airway picture HPS lacks.
- The turn. HPS's cardiopulmonary phase develops within 4–10 days of onset and can go from first breathlessness to respiratory failure within 24 hours; most deaths occur within 24 to 48 hours of that phase beginning.
- Exposure history. Rodents or an enclosed rodent-infested space for HPS; a person for COVID-19. Hantavirus in the Americas is not spread between people.
- The laboratory clue. A five-finding blood-smear screen — thrombocytopenia, hemoconcentration, a granulocytic left shift, absence of toxic granulation and immunoblastic lymphocytes — identified HPS with 96% sensitivity and 99% specificity in the study the spoke cites (Koster et al., Am J Clin Pathol 2001). No such rapid screen exists for COVID-19 because a rapid antigen test does the job.
What the comparison is for. Not to rank the viruses — one is a common, mostly mild respiratory infection, the other a rare, often fatal one — but to make the rare one recognisable inside the common one's season. The practical rule the hantavirus spoke draws is that flu-like illness with severe muscle pain, no upper-airway symptoms and a rodent exposure in the previous two months is a reason to say so at the first medical contact.
Frequently Asked Questions
Is hantavirus deadlier than COVID?
Per person who reaches the cardiopulmonary phase of HPS, 38% die (CDC); per symptomatic COVID-19 illness, 0.2–0.51% (CDC modelled season). Those denominators are different — one counts people already seriously ill, the other everyone who got sick — so the numbers cannot be set in a single ratio.
How do the early symptoms differ?
HPS: fever, exhaustion and intense muscle pain in the thighs, hips and back, often with nausea and diarrhea; runny nose and sore throat are rare and there is no cough early. Omicron-era COVID-19: sore throat, runny nose, fatigue and headache. The rodent exposure 1–8 weeks earlier is the other difference.
How quickly does each become serious?
HPS can move from first breathlessness to respiratory failure within 24 hours, 4–10 days after onset, and most deaths occur within 24–48 hours of that phase beginning. That speed, after a flu-like start, is the feature the hantavirus spoke stresses as unlike a typical respiratory infection.
How common is each?
COVID-19: 10.4–16.7 million US illnesses a year. Hantavirus disease: 890 US cases in 1993–2023, a few dozen a year, concentrated in the rural western states.
This comparison is statistical and epidemiological. It is not medical advice or a risk assessment for any individual; the network's spoke pages cover symptoms, treatment and what to do about exposure for each virus.